✦ LIBER ✦

Biological therapies directed against cells in autoimmune disease

✍ Scribed by Hasler, Paul

Publisher: Springer
Year: 2006
Tongue: English
Weight: 136 KB
Volume: 27
Category: Article
ISSN: 0344-4325
DOI: 10.1007/s00281-006-0013-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The potential utility of B cell-directed

The potential utility of B cell-directed biologic therapy in autoimmune diseases

✍ D. G. Arkfeld 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 368 KB

T-cell targeted therapies in autoimmune

T-cell targeted therapies in autoimmune diseases

✍ Fatima Alnaimat; Paramvir Sidhu; Sujata Sarkar 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

Stem cells and rheumatology: Update on a

Stem cells and rheumatology: Update on adult stem cell therapy in autoimmune diseases

✍ Tyndall, Alan ;Leblanc, Kararina 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB 👁 2 views

Th17 cells in autoimmune demyelinating d

Th17 cells in autoimmune demyelinating disease

✍ Benjamin Matthew Segal 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 131 KB

Biological therapy with monoclonal antib

Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease

✍ M. Prete; F. Perosa; E. Favoino; F. Dammacco 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 251 KB

New prospects for autoimmune disease the

New prospects for autoimmune disease therapy: B cells on deathwatch

✍ E. William St.Clair; Thomas F. Tedder 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 211 KB 👁 2 views

Dr. St.Clair has served on the advisory boards of Genentech, Cellective Therapeutics (now owned by MedImmune), and Human Genome Sciences. Dr. Tedder has Tedder has received consulting fees (more than $10,000 per year) from Cellective Therapeutics (now owned by MedImmune), has given expert testimony